Adherence to subcutaneous biological therapies in patients with inflammatory rheumatic diseases and inflammatory bowel disease: a systematic review

Immunotherapy. 2021 Apr;13(5):433-458. doi: 10.2217/imt-2021-0011. Epub 2021 Feb 9.

Abstract

Aim: To assess adherence to subcutaneous biologicals in adults with inflammatory rheumatic diseases or inflammatory bowel disease and evaluate factors possibly associated with adherence. Materials & methods: Systematic searches were conducted of main databases from January 2000 to June 2019. Results: 41 articles (32 full papers and nine abstracts) were included in the review. Among studies which used a medication possession ratio threshold of ≥80% as the end point, adherence varied from 28.8 to 89.4%. Possible predictors of adherence were older age, professional or family member support, belief in medication necessity, lower concerns about medication and monthly versus weekly administration. Conclusion: Considerable variability in adherence rates across published studies reflects study heterogeneity and the absence of a 'gold standard' to measure adherence.

Keywords: immune-mediated inflammatory diseases; medication adherence; predictors of adherence; subcutaneous biologicals.

Publication types

  • Research Support, Non-U.S. Gov't
  • Systematic Review

MeSH terms

  • Adult
  • Biological Products / administration & dosage
  • Biological Therapy / psychology*
  • Female
  • Humans
  • Inflammatory Bowel Diseases / drug therapy*
  • Inflammatory Bowel Diseases / psychology
  • Injections, Subcutaneous
  • Male
  • Medication Adherence / psychology*
  • Rheumatic Diseases / drug therapy*
  • Rheumatic Diseases / psychology

Substances

  • Biological Products